Published in EMBO J on October 01, 2002
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol (2005) 1.49
Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A (2010) 1.40
Targeting PI3K in Cancer: Any Good News? Front Oncol (2013) 1.18
Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell (2006) 1.07
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell (2009) 1.03
The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation. Mol Cell Biol (2005) 1.01
Signal control through Raf: in sickness and in health. Cell Res (2011) 0.97
Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic. EMBO J (2016) 0.87
Targeted expression of the class II phosphoinositide 3-kinase in Drosophila melanogaster reveals lipid kinase-dependent effects on patterning and interactions with receptor signaling pathways. Mol Cell Biol (2004) 0.84
Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene (2012) 0.84
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett (2015) 0.83
Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS One (2013) 0.83
Class II phosphoinositide 3-kinase C2alpha: what we learned so far. Int J Biochem Mol Biol (2011) 0.82
Phosphoinositide 3-kinase C2β regulates RhoA and the actin cytoskeleton through an interaction with Dbl. PLoS One (2012) 0.79
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC? J Thorac Oncol (2016) 0.78
RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Oncotarget (2015) 0.78
The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors. Glob J Biochem (2011) 0.78
Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. Oncotarget (2016) 0.77
Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells. PLoS One (2013) 0.75
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther (2016) 0.75
Targeting the Mammalian Target of Rapamycin in Lung Cancer. Am J Med Sci (2016) 0.75
Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. Sci Rep (2016) 0.75
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (1997) 5.43
3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol (1998) 5.04
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science (1999) 4.77
Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med (2001) 4.07
PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J (1994) 3.39
1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc Natl Acad Sci U S A (1994) 3.37
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays (2002) 2.37
Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol (1999) 2.35
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol (2000) 1.55
Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence on signal strength. J Biol Chem (1997) 1.54
Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases. Biochem J (2000) 1.44
Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem (1998) 1.38
The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res (1998) 1.37
Insulin activates the alpha isoform of class II phosphoinositide 3-kinase. J Biol Chem (1999) 1.23
Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol (2001) 1.23
Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J (1999) 1.19
Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene (2001) 1.14
Binding to the platelet-derived growth factor receptor transiently activates the p85alpha-p110alpha phosphoinositide 3-kinase complex in vivo. J Biol Chem (1996) 0.94
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A (2008) 2.81
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature (2004) 2.73
Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J (2007) 2.66
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35
Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol (2006) 2.29
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med (2008) 2.25
The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal (2010) 2.15
A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep (2008) 2.09
Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet (2009) 2.06
Management and outcome of healthy women with a persistently elevated beta-hCG. Gynecol Oncol (2007) 2.01
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet (2002) 1.98
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98
Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 1.97
PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci Signal (2011) 1.95
The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol (2012) 1.94
Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol (2004) 1.81
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Primary human alveolar type II epithelial cell chemokine release: effects of cigarette smoke and neutrophil elastase. Am J Respir Cell Mol Biol (2004) 1.78
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol (2004) 1.71
The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol (2006) 1.70
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Targeting of the F-actin-binding protein drebrin by the microtubule plus-tip protein EB3 is required for neuritogenesis. Nat Cell Biol (2008) 1.70
Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study. J R Soc Med (2008) 1.65
Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci (2009) 1.65
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 1.61
Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages. J Immunol (2007) 1.61
Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics (2002) 1.60
Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab (2009) 1.59
Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet (2011) 1.51
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res (2003) 1.51
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J (2007) 1.48
The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res (2009) 1.47
Retracted Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem (2002) 1.40
Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A (2010) 1.40
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci (2008) 1.39
Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. BJU Int (2012) 1.39
Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol (2007) 1.38
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal (2006) 1.38
Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol (2005) 1.37
The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med (2008) 1.34
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett (2007) 1.33
Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol (2008) 1.31
The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1. J Cell Biol (2010) 1.28
Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood (2007) 1.27
Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med (2002) 1.25
Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics (2007) 1.24
The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol (2007) 1.23
Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol (2007) 1.23
Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics (2002) 1.22
The maternally transcribed gene p57(KIP2) (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. Hum Mol Genet (2002) 1.21
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal (2013) 1.20
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol Cell Proteomics (2005) 1.20
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 1.19
Primary human alveolar type II epithelial cell CCL20 (macrophage inflammatory protein-3alpha)-induced dendritic cell migration. Am J Respir Cell Mol Biol (2004) 1.19
Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS One (2007) 1.18
Gestational trophoblastic tumours: an update for 2014. Curr Oncol Rep (2014) 1.17
Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.15
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.15
Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics (2005) 1.14
CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood (2009) 1.14
Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med (2002) 1.13
Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. Am J Respir Cell Mol Biol (2008) 1.13
Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol (2007) 1.12
The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol (2009) 1.12
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood (2010) 1.12
Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem (2003) 1.11
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2007) 1.10
PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun (2011) 1.10
Innate immune responses to bacterial ligands in the peripheral human lung--role of alveolar epithelial TLR expression and signalling. PLoS One (2011) 1.09
The stability of silver nanoparticles in a model of pulmonary surfactant. Environ Sci Technol (2013) 1.09
Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell (2006) 1.07
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
The p90 RSK family members: common functions and isoform specificity. Cancer Res (2013) 1.07
Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene (2002) 1.07
Dynamic cofilin phosphorylation in the control of lamellipodial actin homeostasis. J Cell Sci (2007) 1.06
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res (2009) 1.06
Assessment of cell line models of primary human cells by Raman spectral phenotyping. Biophys J (2010) 1.06
Structural and membrane binding analysis of the Phox homology domain of phosphoinositide 3-kinase-C2alpha. J Biol Chem (2006) 1.05
Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol (2013) 1.04
A parallel proteomic and metabolomic analysis of the hydrogen peroxide- and Sty1p-dependent stress response in Schizosaccharomyces pombe. Proteomics (2006) 1.04
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J (2012) 1.03
Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion. J Cell Biol (2010) 1.03
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res (2009) 1.02
Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol (2010) 1.01
Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med (2013) 1.01